{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Losoxantrone_Hydrochloride",
  "nciThesaurus": {
    "casRegistry": "132937-89-4",
    "chebiId": "",
    "chemicalFormula": "2C22H27N5O4.4ClH.H2O",
    "definition": "The hydrochloride salt form of losoxantrone, an anthrapyrazole-based antineoplastic antibiotic. Losoxantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits topoisomerase II, thereby inhibiting DNA replication and repair as well as RNA and protein synthesis. Losoxantrone is less cardiotoxic than doxorubicin.",
    "fdaUniiCode": "W6E275IURX",
    "identifier": "C72077",
    "preferredName": "Losoxantrone Hydrochloride",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C2107"
    ],
    "synonyms": [
      "LOSOXANTRONE HYDROCHLORIDE",
      "Losoxantrone HCl",
      "Losoxantrone Hydrochloride",
      "Losoxantrone Hydrochloride Hydrate"
    ]
  }
}